Strides CEO: US COMPETES Act Creates Quality Differentiator

Examining Upcoming HIV Therapies

16 Feb 2022

The $1-10m penalties prescribed on erring global manufacturers in the US COMPETES Act will create quality differentiators, Strides CEO R Ananthanarayanan tells Scrip. He also discusses the potential that Mark Cuban’s firm holds for Indian companies and Strides' evaluation of upcoming HIV therapies.

Concept Of Manufacturing In US — US COMPETES Act Has Implications For Manufacturing In US And Out • Source: Alamy

In February, the US House of Representatives passed the America Creating Opportunities for Manufacturing Pre-Eminence in Technology and Economic Strength Act (The America COMPETES Act), aimed at providing resources for the expansion of domestic output.

Significantly, it also allows the US Food and Drug Administration (FDA) to impose monetary penalties of $1-10m on manufacturers for falsifying data and test results and destroying documents in advance...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

How Much Does Biopharma Contribute To The US Economy?

19 May 2025

• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

16 May 2025

• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.